Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

Journal of Heart and Lung Transplantation

Volumn 30, Issue 6, 2011, Pages 632-643

  Barst, Robyn J ^a,h   Oudiz, Ronald J ^b   Beardsworth, Anthony ^c   Brundage, Bruce H ^d   Simonneau, Gerald ^e   Ghofrani, Hossein A ^f   Sundin, David P ^c   Gali, Nazzareno ^g  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Heart Institute of the Cascades   (United States)

^e Antoine Bclre Universit Hôpital   (France)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g Institute of Cardiology   (Italy)

^h NONE   (United States)

Author keywords

bosentan; concomitant therapy; phosphodiesterase inhibitors; pulmonary arterial hypertension; tadalafil

Indexed keywords

BOSENTAN; PLACEBO; TADALAFIL;

ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPISTAXIS; EXERCISE TEST; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; LIMB PAIN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NOSE CONGESTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARBOLINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79955845135     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2010.11.009     Document Type: Article

References (38)

1. N. Galie, and L.J. Rubin New insights into a challenging diseasea review of the Third World Symposium on Pulmonary Arterial Hypertension J Am Coll Cardiol 43 suppl S 2004 1S 90S editors
2. D.B. Badesch, V.F. Tapson, and M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease A randomized, controlled trial Ann Intern Med 132 2000 425 434 (Pubitemid 30149039)
3. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 302
4. R.J. Barst, D. Langleben, and A. Frost Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 441 447 (Pubitemid 38187114)
5. R.J. Barst, D. Langleben, and D. Badesch Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan J Am Coll Cardiol 47 2006 2049 2056
6. R.L. Benza, S. Mehta, and A. Keogh Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan J Heart Lung Transplant 26 2007 63 69 (Pubitemid 46096748)
7. R.L. Benza, R.J. Barst, and N. Galie Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival Chest 134 2008 775 782
8. N. Galie, H.A. Ghofrani, and A. Torbicki Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157 (Pubitemid 41653106)
9. N. Galie, H. Olschewski, and R.J. Oudiz Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
10. N. Galie, B.H. Brundage, and H.A. Ghofrani Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
11. H. Olschewski, G. Simonneau, and N. Galie Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329 (Pubitemid 34815354)
12. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903 (Pubitemid 34984638)
13. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804 (Pubitemid 34229650)
14. R. Voswinckel, F. Reichenberger, and H. Gall Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension Pulmon Pharmacol Ther 22 2009 50 56
15. D.B. Badesch, S.H. Abman, and G. Simonneau Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines Chest 131 2007 1917 1928 (Pubitemid 46981654)
16. N. Galie, A. Torbicki, and R.J. Barst Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology Eur Heart J 25 2004 2243 2278
17. V.V. McLaughlin, and M.D. McGoon Pulmonary arterial hypertension Circulation 114 2006 1417 1431 (Pubitemid 44454562)
18. V.V. McLaughlin, S.L. Archer, and D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation 119 2009 2250 2294
19. L.C. Rubin, S.H. Abman, and G.S. Ahearn Diagnosis and management of pulmonary artery hypertension: ACCP evidence-based clinical practice guideline Chest 126 suppl 1 2004 1S 92S
20. N. Galie, M.M. Hoeper Task Force Members Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
21. N. Galie, M.M. Hoeper Task Force Members Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Respir J 34 2009 1219 1263
22. R.L. Benza, M.H. Park, and A. Keogh Management of pulmonary arterial hypertension with a focus on combination therapies J Heart Lung Transplant 26 2007 437 446 (Pubitemid 46602007)
23. V.V. McLaughlin, R.J. Oudiz, and A. Frost Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263 (Pubitemid 44924827)
24. G. Simonneau, L.J. Rubin, and N. Galie Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
25. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
26. S.L. Archer, and E.D. Michelakis An evidence-based approach to the management of pulmonary arterial hypertension Curr Opin Cardiol 21 2006 385 392 (Pubitemid 44315072)
27. R.J. Barst Updated evidence-based treatment algorithm for pulmonary arterial hypertension J Am Coll Cardiol 54 suppl 10 2009 S78 S84
28. S.H. Lee, and L.J. Rubin Current treatment strategies for pulmonary arterial hypertension J Intern Med 258 2005 199 215 (Pubitemid 41243051)
29. D.S. O'Callaghan, and S.P. Gaine Combination therapy and new types of agents for pulmonary arterial hypertension Clin Chest Med 28 2007 169 185 (Pubitemid 46330547)
30. N. Galie, D. Badesch, and R. Oudiz Ambrisentan therapy for pulmonary arterial hypertension J Am Coll Cardiol 46 2005 529 535 (Pubitemid 41040298)
31. A.E. Frost, D. Langleben, and R. Oudiz The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect Vasc Pharmacol 43 2005 36 39 (Pubitemid 40828831)
32. R.E. Wrishko, J. Dingemanse, and A. Yu Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects J Clin Pharmacol 48 2008 610 618 (Pubitemid 351503516)
33. P.C. Austin, M.M. Mamdani, and C. van Walraven Quantifying the impact of survivor treatment bias in observational studies J Eval Clin Pract 12 2006 601 612 (Pubitemid 44715469)
34. M.J. Glesby, and D.R. Hoover Survivor treatment selection bias in observational studiesexamples from the aids literature Ann Intern Med 124 1996 999 1005
35. R. Hubbard, I. Johnston, and J. Britton Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study Chest 113 1998 396 400 (Pubitemid 28110017)
36. M.M. Humbert, O.M. Sitbon, and A.M. Chaouat Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
37. N. Galie, A. Manes, and L. Negro A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403
38. H.A.M. Ghofrani, M.W.M. Wilkins, and S.M. Rich Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension Circulation 118 2008 1195 1201